Monaco F, De Conti L, Vodret S, Zanotta N, Comar M, Manzotti S, et al
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
At-home therapies include injections, capsules, troches, or sprays
Vegan collagen supplements are also available, thanks to advances in technology in which genetically modified yeast and bacteria are used
Our targeted wellness injections deliver essential nutrients directly into the bloodstream for fast absorption, increased energy, stronger immunity, and improved skin health
